Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joanne Eastaugh is active.

Publication


Featured researches published by Joanne Eastaugh.


European Heart Journal | 2003

The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis.

John G.F. Cleland; Karl Swedberg; Ferenc Follath; Michel Komajda; Alain Cohen-Solal; J.C. Aguilar; Rainer Dietz; Antonello Gavazzi; Richard J. Hobbs; Jerzy Korewicki; Hugo Madeira; V.S. Moiseyev; István Préda; W. H. Van Gilst; J Widimsky; Nick Freemantle; Joanne Eastaugh; James Mason

BACKGROUND The European Society of Cardiology (ESC) has published guidelines for the investigation of patients with suspected heart failure and, if the diagnosis is proven, their subsequent management. Hospitalisation provides a key point of care at which time diagnosis and treatment may be refined to improve outcome for a group of patients with a high morbidity and mortality. However, little international data exists to describe the features and management of such patients. Accordingly, the EuroHeart Failure survey was conducted to ascertain if appropriate tests were being performed with which to confirm or refute a diagnosis of heart failure and how this influenced subsequent management. METHODS The survey screened consecutive deaths and discharges during 2000-2001 predominantly from medical wards over a 6-week period in 115 hospitals from 24 countries belonging to the ESC, to identify patients with known or suspected heart failure. RESULTS A total of 46788 deaths and discharges were screened from which 11327 (24%) patients were enrolled with suspected or confirmed heart failure. Forty-seven percent of those enrolled were women. Fifty-one percent of women and 30% of men were aged >75 years. Eighty-three percent of patients had a diagnosis of heart failure made on or prior to the index admission. Heart failure was the principal reason for admission in 40%. The great majority of patients (>90%) had had an ECG, chest X-ray, haemoglobin and electrolytes measured as recommended in ESC guidelines, but only 66% had ever had an echocardiogram. Left ventricular ejection fraction had been measured in 57% of men and 41% of women, usually by echocardiography (84%) and was <40% in 51% of men but only in 28% of women. Forty-five percent of women and 22% of men were reported to have normal left ventricular systolic function by qualitative echocardiographic assessment. A substantial proportion of patients had alternative explanations for heart failure other than left ventricular systolic or diastolic dysfunction, including valve disease. Within 12 weeks of discharge, 24% of patients had been readmitted. A total of 1408 of 10434 (13.5%) patients died between admission and 12 weeks follow-up. CONCLUSIONS Known or suspected heart failure comprises a large proportion of admissions to medical wards and such patients are at high risk of early readmission and death. Many of the basic investigations recommended by the ESC were usually carried out, although it is not clear whether this was by design or part of a general routine for all patients being admitted regardless of diagnosis. The investigation most specific for patients with suspected heart failure (echocardiography) was performed less frequently, suggesting that the diagnosis of heart failure is still relatively neglected. Most men but a minority of women who underwent investigation of cardiac function had evidence of moderate or severe left ventricular dysfunction, the main target of current advances in the treatment of heart failure. Considerable diagnostic uncertainty remains for many patients with suspected heart failure, even after echocardiography, which must be resolved in order to target existing and new therapies and services effectively.


European Heart Journal | 2003

The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe Part 2 : treatment

Michel Komajda; F. Follath; Karl Swedberg; John G.F. Cleland; J.C. Aguilar; A. Cohen-Solal; R. Dietz; A. Gavazzi; W. H. Van Gilst; Richard J. Hobbs; Jerzy Korewicki; H.C. Madeira; V.S. Moiseyev; István Préda; J Widimsky; Nick Freemantle; Joanne Eastaugh; J. Mason

Background National surveys suggest that treatment of heart failure in daily practice differs from guidelines and is characterized by underuse of recommended medications. Accordingly, the Euro Heart Failure Survey was conducted to ascertain how patients hospitalized for heart failure are managed in Europe and if national variations occur in the treatment of this condition. Methods The survey screened discharge summaries of 11 304 patients over a 6-week period in 115 hospitals from 24 countries belonging to the ESC to study their medical treatment. Results Diuretics (mainly loop diuretics) were prescribed in 86.9% followed by ACE inhibitors (61.8%), beta-blockers (36.9%), cardiac glycosides (35.7%), nitrates (32.1%), calcium channel blockers (21.2%) and spironolactone (20.5%). 44.6% of the population used four or more different drugs. Only 17.2% were under the combination of diuretic, ACE inhibitors and beta-blockers. Important local variations were found in the rate of prescription of ACE inhibitors and particularly beta-blockers. Daily dosage of ACE inhibitors and particularly of beta-blockers was on average below the recommended target dose. Modelling-analysis of the prescription of treatments indicated that the aetiology of heart failure, age, co-morbid factors and type of hospital ward influenced the rate of prescription. Age 70 years, in patients with respiratory disease and increased in cardiology wards, in ischaemic heart failure and in male subjects. Prescription of cardiac glycosides was significantly increased in patients with supraventricular tachycardia/atrial fibrillation. Finally, the rate of prescription of antithrombotic agents was increased in the presence of supraventricular arrhythmia, ischaemic heart disease, male subjects but was decreased in patients over 70. Conclusion Our results suggest that the prescription of recommended medications including ACE inhibitors and beta-blockers remains limited and that the daily dosage remains low, particularly for beta-blockers. The survey also identifies several important factors including age, gender, type of hospital ward, co morbid factors which influence the prescription of heart failure medication at discharge.


European Journal of Heart Failure | 2000

The Euro Heart Failure Survey of the EUROHEART survey programme. A survey on the quality of care among patients with heart failure in Europe

J.G.F. Cleland; Karl Swedberg; Alain Cohen-Solal; J Cosin-Aguilar; Rainer Dietz; Ferenc Follath; Antonello Gavazzi; Richard Hobbs; Jerzy Korewicki; Hugo Madeira; István Préda; W.H. van Gilst; J Widimsky; Viatcheslav Mareev; James Mason; Nick Freemantle; Joanne Eastaugh

The EUROHEART programme is a rolling programme of cardiovascular surveys among the member nations of the European Society of Cardiology (ESC). These surveys will provide information on the nature of cardiovascular disease and its management. This manuscript describes a survey into the nature and management of heart failure.


European Journal of Heart Failure | 2003

The heart failure revascularisation trial (HEART): rationale, design and methodology.

John G.F. Cleland; Nick Freemantle; Stephen G. Ball; Robert S. Bonser; P. Camici; Sudipta Chattopadhyay; David P. Dutka; Joanne Eastaugh; John R. Hampton; S. Large; Michael S. Norell; Dudley J. Pennell; J. Pepper; S. Sanda; Roxy Senior; D. Smith

Most patients with heart failure due to left ventricular systolic dysfunction (LVSD) secondary to coronary artery disease (CAD) have evidence of myocardium in jeopardy (reversible ischaemia and/or stunning hibernation). It is not known whether revascularisation in such cases is safe or beneficial.


European Journal of Heart Failure | 2007

Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge

N.K. Khan; Kevin Goode; John G.F. Cleland; Alan S. Rigby; Nick Freemantle; Joanne Eastaugh; Andrew L. Clark; Ramesh de Silva; Melanie Calvert; Karl Swedberg; Michael Komajda; Viu Mareev; Ferenc Follath

Most patients suspected of having heart failure (HF) will get a 12‐lead electrocardiogram (ECG) but its utility for excluding HF or assisting in its management has rarely been investigated.


European Journal of Heart Failure | 2004

Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe†

Jörg Muntwyler; Alain Cohen-Solal; Nick Freemantle; Joanne Eastaugh; John G.F. Cleland; Ferenc Follath

To study the role of sex, age and concomitant diseases for prescription of cardiovascular drugs among patients with heart failure cared for in the community.


European Journal of Heart Failure | 2005

The diagnosis of heart failure in European primary care: The IMPROVEMENT Programme survey of perception and practice

Fd Richard Hobbs; Jerzy Korewicki; John G.F. Cleland; Joanne Eastaugh; Nick Freemantle

To examine European primary care physicians (PCPs) views on diagnosis of heart failure and compare perceptions with actual practice.


International Journal of Pharmacy Practice | 2007

Clinical medication review by a pharmacist of elderly people living in care homes: pharmacist interventions

David Phillip Alldred; Arnold Zermansky; Duncan Petty; David K. Raynor; Nick Freemantle; Joanne Eastaugh; Peter Bowie

Objectives To describe the rate and nature of pharmacist interventions following clinical medication review of elderly people living in care homes.


Journal of Clinical Pharmacy and Therapeutics | 2002

Using effectiveness studies for prescribing research, part 1.

Nick Freemantle; Joanne Eastaugh

The process of evaluating pharmaceuticals has become highly conceptualized in contrast to the lack of formal rules for assessing effects of interventions on practice. We argue that clinical audit is a key factor prior to instigating an intervention and that randomized controlled evaluations are preferable. We discuss the need for small‐scale experiments prior to full trials to validate the underlying concept of an intervention with the recognition that different approaches may be necessary. This includes open rather than blind assessments and greater emphasis on qualitative issues during development of interventions followed by quantitative appraisal of their impact.


The Lancet | 2002

Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey

John G.F. Cleland; Alain Cohen-Solal; J. Cosin Aguilar; Rainer Dietz; Joanne Eastaugh; Ferenc Follath; Nick Freemantle; Antonello Gavazzi; W. H. Van Gilst; F. D. R. Hobbs; Jerzy Korewicki; Hugo Madeira; István Préda; Karl Swedberg; J Widimsky

Collaboration


Dive into the Joanne Eastaugh's collaboration.

Top Co-Authors

Avatar

Nick Freemantle

University College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Karl Swedberg

University of Gothenburg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John G.F. Cleland

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

J Widimsky

University of Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge